Clovis | 3 buy scenarios | One trial at a timeGreat run Clovis had the last days. However i prefer not to buy into runs and wait till my requirements are met.
I marked 3 possible places where i would buy if the following would happen:
- Price gets above the level
- Open and close of a monthly candle above the level, then buy
- Targets are based on the next resistance level
- Stop- Loss: None
Good luck
Disclaimer:
- This information does not constitute as financial advice and is only for educational purposes. I am not your financial advisor.
- You trade entirely at your own risk
- Make your own research
- Finance and trading is evil, capitalism is bad, duh ;)
Clovis
Clovis Oncology CLVS Option CallsBased on my research, I think that the $3 strike price expiring July 15, with the price of $0.21 or lower is what I would pick right now.
As you know, the OTM options can be profitable even if they don`t reach the strike price.
If the stock moves closer to the strike price after you enter the trade, or if there is a rapid increase in Implied Volatility, you can sell the option for a profit.
My personal goal is to transform $10k into $1Million from options trading.
Thank you for viewing my out of the money option calls and puts ideas!
Clovis Oncology Curing it. CLVSAnother bullish looking pick in the same industry. We love impulses, especially we catch them before tehy make themselves apparent.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
CLVS back on the low lowCLVS is now back at its November 2020 low. The interesting part of this trend is that it also managed to test, hold, and bounce off of an almost identical level (strong support?). As of Friday afternoon shares retested an interim area of higher traffic that was support earlier in August and late July but now appears to have become a resistance level over the last 3 sessions at least. With the "short squeeze stocks" conversation building steam, it could be interesting for CLVS. Finviz shows the short float percentage at 27% right now.
" The biotech sector may also host some of the other heavily shorted stocks. Phase trial data, scientific reports, and the like all play a role in directional momentum. In this case, Clovis has felt some pressure over the last few quarters. Clinical data on its FAP-2286 platform, along with missed earings, haven’t helped the cause. Then you’ve got news of large, multi-million dollar fundraising initiatives adding more pressure as well. Needless to say, it has happened to hopefully advance the company’s pipeline...Clovis specializes in developing cancer treatments. Its lead candidate Rubraca is an oral treatment being developed in multiple types of tumors. These include ovarian and prostate cancers. It’s approved in the US for maintenance treatment in adults with recurrent epithelial, ovarian, fallopian tube, or primary peritoneal cancers...As far as CLVS being considered one of the “short squeeze stocks,” outlets show that the penny stock’s short-interest sits around 27%. Of course, it isn’t as high as some of the others on this list. However, anything over 20%, by most accounts, can be considered high. "
Quote Source & Read More: 4 Short Squeeze Penny Stocks To Watch After SPRT Stock’s 1,309% Run
CLVS 786 Fib Line Holding (For Now)Took the chart back out to March of last year to do a little fib retracement. Wouldn't you know, CLVS has been channel bound for a minute between the 618 and 786 fib lines with pretty clear support and resistance levels at each. Since it retraced back to the 786 again and is holding (for now), volume is likely going to be the "friend" or "foe" depending on how you're looking to trade this stock. You've also got the 50DMA to keep track of, which has also been a decent level of resistance over the past week or so.
Fundamentally, I'm looking to see if speculation starts building later down the line after they announced that they initiated sponsored clinical development of FAP-2286 with the Phase 1/2 LuMIERE clinical trial in patients with FAP-positive solid tumors which is now enrolling. Either way, cancer stocks seem to be picking up some steam . Whether it's targeted treatments or drug delivery technology, oncology is beginning to take its own slice of biotech lately.
CLVS Clovis Oncology Price TargetCLVS Clovis Oncology is sitting at a strong support area ready for a bounce.
My Price target is the 10usd resistance level
On 5/5/2021 HC Wainwright brokerage Lowered the Price Target for CLVS Clovis Oncology to Buy Rating from $13.00 to$12.00
$CLVS lower volume on descending prices, lower short pressure Lower volume on descending prices, lower short pressure
it means...
the price wants to go higher.
Clovis Oncology - Possible bottoming formationCLVS has been beat up for a loooong time.
On a 3 hr chart it appears that we are seeing a bottoming inver H&S formation. Company also is making positive news about Rubraca that just met the primary endpoint of significantly improving Progression-Free Survival vs. Chemotherapy.
Completely a momentum based trade with a tight stop loss.
PS Never ever take any of my posts as financial advice.
$CLVS Triangular TIPZ close to the X'zCLOVIS maker of FDA approved Rubraca® which is a treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy. www.rubraca.com
Sitting at a pretty interesting area right now, sure it will get some more movement soon as we are at a crucial area. Plus last time I reviewed the sec docs it seemed to me like they were lowering net-losses & striving towards profits.
DYI: www.sec.gov
There's nowhere else to go...We have a triple rejection of the sub 8.60 price range on the weekly candles, setup doesn't get much better than that. Consolidation has taken longer than expected but what else is new haha.
$CLVS cup and handle fully formed.I would be cautious of the handle getting any longer. Other than that it looks to be at the end of consolidation.
Imminent break to the upside for Clovis Oncology.I think we will see a sharp move this month. From reading the chart alone I am wagering it's going to be a bullish move... even though the fundamentals of the company are up for debate.
Bullish View on Clovis OncologyBullish view on Clovis Oncology as it breaks $30 price resistance.
CLVS jumped 13% last Wednesday as sales of its Rubraca drug used to treat ovarian cancer patients went up 33% compared to previous quarter.
One possible path for CLVSA few thoughts on CLVS. May not pan out, but this is a bullish scenario.
Reasons the bull scenario could play out from a technical standpoint:
1. Move up to $99 was a clear 5 waves. It looks to have recently completed the ABC correction into a perfect golden pocket 61.8 to 65% retracement.
2. Wave C was an ending diagonal. CLVS has broken out of the diagonal to the upside after a throw over to the downside (a common occurrence in diagonals).
3. Wave 1 up of the new trend has already retraced about 50%. If it gets to the $53-54 range soon, that will make a 61.8% retracement of wave 1 up.
Aggressive traders might be looking to buy the drop to the $53 range hoping the above scenario is correct.
More conservative traders might wait for it to break the high of wave 1 around $63 for confirmation of a new uptrend.
I have no position at this time, but will be watching closely and may enter a position in the future.
Obviously, the bear scenario (which does not really need much chart elaboration) would be that the current downward movement continues to the lower trendline, possibly testing the low $40's in the near future.